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Abstract 
Purpose: To investigate the effect of Astragalus membranaceus (Fisch.) Bunge. extract (AMBE) on 
streptozotocin-induced diabetic rats. 
Methods: The aqueous extract of AMB was obtained by steeping the dried Astragalus membranaceus 
(Fisch.) Bunge. in water at 60 oC three times, each for 1 h, before first drying in an oven at 100 oC and 
then freeze-drying the last extract thus obtained. Diabete model rats was induced by a single 
intraperitoneal injection of a freshly prepared solution of streptozotocin (50 mg/kg). The rats were 
randomly divided into 6 groups of ten rats each: negative control group, normal control group, reference 
group (glibenclamide1 mg/kgbody weight) as well as AMB extract groups, namely, 40, 80 and 160 
mg/kg body weight. Antihyperglycemic effect was measured by blood glucose and plasma insulin levels. 
Oxidative stress was evaluated in liver and kidney by antioxidant markers, viz, lipidperoxidation (LPO), 
superoxide dismutase (SOD), reduced glutathione (GSH), glutathione peroxidase (GPx) and catalase 
(CAT), while blood serum levels of creatinine and urea were also determined in both diabetic control 
and treated rats. 
Results: Compared with diabetic rats, oral administration of AMBE at a concentration of 160 mg/kg 
daily for 30 days showed a significant decrease in fasting blood glucose (109.438 ± 3.52, p < 0.05) and 
increased insulin level (13.96 ± 0.74, p < 0.05). Furthermore, it significantly reduced biochemical 
parameters (serum creatinine, 0.86 ± 0.29, p < 0.05) and serum urea (45.14 ± 1.79, p < 0.05). The 
treatment also resulted in significant increase in GSH (49.21 ± 2.59, p < 0.05), GPx (11.96 ± 1.16, p < 
0.05), SOD (14.13 ± 0.49, p < 0.05), CAT (83.25 ± 3.14, p < 0.05) level in the liver and kidney of 
diabetic rats. 
Conclusion: The results suggest that AMBE may effectively normalize impaired antioxidant status in 
streptozotocin-induced diabetes in a dose-dependent manner. AMBE has a protective effect against 
lipid peroxidation by scavenging free radicals and is thus capable of reducing the risk of diabetic 
complications. 
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Diabetes mellitus, a metabolic disorder 
characterized by hyperglycemia, dyslipidemia, 
insulin resistance, insufficient insulin secretion, is 
a major public health problem in developing and 
developed countries. The increase in diabetic 
cases has been partly attributed to consumption 
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of calorie-rich diet, obesity and sedentary life 
style [1]. Developed countries such as India, 
China and the United States of America are 
presently the countries with the leading number 
of diabetics. Furthermore, seven percent of 
residents of the United States are diabetic. 
 
Though diabetes is a non-communicable 
disease, it is considered to be one of the five 
leading causes of death in the world [2]. The 
disease is a complex metabolic disorder of the 
endocrine system with dynamic expression of 
pathological disequilibria, resulting in various 
micro and macro vascular complications. It is 
characterized by high blood glucose levels 
(hyperglycemia) due to the inability of the body’s 
cells to utilize glucose properly [3].  
 
The increased blood glucose levels in diabetes 
produce superoxide anions, which generate 
hydroxyl radicals via Haber–Weiss reaction, 
resulting in peroxidation of membrane lipids and 
protein glycation. This leads to oxidative damage 
of cell membranes. These radicals further 
damage other important biomolecules including 
carbohydrates, proteins and deoxyribonucleic 
acid (DNA) [4]. 
 
In diabetes, oxidative stress has been found 
mainly due to an increased production of oxygen 
free radicals and a sharp reduction of antioxidant 
defenses [5]. The endogenous antioxidant 
enzymes (e.g., SOD, CAT, GSH and GPx) are 
responsible for the detoxification of deleterious 
oxygen radicals [6]. Antioxidants thus play an 
important role to protect the human body against 
damage caused by reactive oxygen species [4]. 
Hence, compounds with both hypoglycemic and 
antioxidative properties would be useful 
antidiabetic agents [7]. 
 
Medicinal plants are widely used by the 
population of developing countries as alternative 
therapy. In China, hundreds of plants are used 
traditionally for the management of diabetes 
mellitus. Unfortunately, only a few of such 
Chinese medicinal plants have received scientific 
scrutiny. Despite the long traditional use of 
Astragalus membranaceus (Fisch.) Bunge.  
 
In diabetes [8,9], no systematic pharmacological 
work has been carried out on this plant. The 
present study was therefore designed to study 
the antioxidant potential and hypoglycemic effect 
of Astragalus membranaceus (Fisch.) Bunge. 





Plant material and extraction 
 
Samples of Astragalus membranaceus (Fisch.) 
Bunge. were collected from Bozhou City, Anhui 
Province in China in May 2015. Taxonomic 
identification of the plant was performed by 
Professor Jun-li Meng of Shandong University in 
China. A voucher specimen (no. AMB 20150402) 
was deposited in the herbarium of College of 
Pharmacy, Shandong University, China for future 
reference. 
 
The whole plant of Astragalus membranaceus 
(Fisch.) Bunge. was dried in a drying oven at 100 
oC for 12 h. The aqueous extract of AMB was 
obtained by steeping the dried Astragalus 
membranaceus (Fisch.) Bunge. in water at 60 oC 
three times, each for 1 h before first drying in an 
oven and then freeze-drying the last extract thus 
obtained. One gram powder was obtained from 




SPF Male Wistar rats, weighing 180 – 200 g, 
were provided by the Experimental Animal 
Center of Shandong Province (Certificate no. 
SYXK2005 - 0002). The animals had free access 
to food and water, and were allowed to 
acclimatize for at least one week before use. The 
rat experiment was approved by the Animal Care 
and Use Committee of Shandong University 
(approval ref no. 20101004) and was carried out 
in compliance with Directive 2010/63/EU on the 





The rats were randomly divided into 6 groups of 
ten rats each: negative control group, control 
group, reference group (glibenclamide 1 mg/kg 
body weight) as well as AMB extract groups, 
namely, 40, 80 and 160 mg/kg body weight. 
Treatments (in aqueous solution) were given 
orally once daily for 30 days.  
 
Induction of experimental diabetes 
 
The animals were fasted overnight and diabetes 
was induced by a single intraperitoneal injection 
of a freshly prepared solution of streptozotocin 
(50 mg/kg) in citrate buffer (pH 4.5) [11]. The 
animals were allowed to drink 5 % glucose 
solution to overcome the drug induced 
hypoglycemia [12]. On the third day of STZ-
injection, the rats were fasted for 6 h and blood 
was withdrawn by retroorbital puncture under 
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ether anesthesia. Rats with moderate diabetes 
having hyperglycemia (that is, with blood glucose 





Rats were fasted overnight and the blood was 
withdrawn by retro orbital puncture under light 
ether anesthesia on the days 1, 15 and 30 post-
induction to determine blood glucose and plasma 
insulin level. The change in body weight was 
observed throughout treatment period in the 
experimental animals. At the end of 30 days, the 
animals were deprived of food overnight and 
sacrificed by cervical decapitation for 
biochemical parameters (hemoglobin, 
glycosylated Hb, total protein, serum creatinine, 
serum urea) and antioxidant enzyme (SOD, CAT, 
GSH, GPx, LPO) estimation. Blood was collected 
from the heart in two different tubes, i.e. one with 
anticoagulant for plasma, and another without 
anticoagulant for serum separation. Serum was 
separated by centrifugation 3500 rpm at 25 oC 
for 10 min. Fasting blood glucose was estimated 
by O-toluidine method [14]. Plasma insulin level 
was assayed by the radio-immunoassay method. 
All other biochemical tests were carried out in our 
lab by using commercial kits obtained from Erba 
diagnostic Mannheim Gmbh, Germany. 
 
Oral glucose tolerance test 
 
The rats were divided into four groups of 6 
animals (n = 6) each. Group I served as control 
and received distilled water. Group II served as 
diabetic control and received distilled water. 
Group III served as positive control, received 
glibenclamide (1 mg/kg). Group IV received 
AMBE 80 gm/kg orally. The rats were fasted for 
18 h and the test performed by oral 
administration of glucose (2 g/kg) to diabetic and 
normal rats 30 min after dosing. Blood samples 
were collected from the retro-orbital plexus of the 
eye (under light ether anesthesia) immediately (0 
h), 30, 60, 90, and 120 min after the glucose 
administration and the blood glucose levels were 
estimated. 
 
Assay of antioxidant enzyme 
 
The liver and kidney were carefully removed, 
weighed and washed in ice-cold saline to remove 
the blood. Then both were sliced separately into 
pieces and homogenized with buffer containing 
0.25 M sucrose and 0.1 M TrisHCl buffer (pH 
7.4). The homogenate was centrifuged at 3000 
rpm for 10 min at 0 oC in cold centrifuge. The 
supernatant was separated and used for various 
antioxidant enzyme estimations. 
 
The levels of lipid peroxidation (LPO), speroxide 
dismutase (SOD), catalase (CAT), gutathione 
peroxidase (GPx) and gluathione (GSH) in liver 





Data are presented as mean ± standard 
deviation (SD), and were analyzed by one-way 
ANOVA followed by Tukey’s multiple comparison 
using SPSS 17.0 software for Windows. 
Differences were considered statistically 




Effect of AMBE on blood glucose and plasma 
insulin  
 
Fasting blood glucose levels in the normal 
control group of rats remained unchanged during 
the course of the experiment. In diabetic groups, 
level of fasting blood glucose was significantly (p 
< 0.01) higher and the plasma insulin level was 
significantly decreased as compared to normal 
group. On the other hand, administration of 
AMBE for 30 days was found to lower the blood 
glucose and increase the insulin level 
significantly (p < 0.01) in a dose dependent 
manner when compared with control groups 
(Tables 1 and 2). 
 
Table 1: Effect of AMBE on blood sugar level in rats (mean ± SD, n = 10) 
 
Group Dose(mg/kg)  Blood sugar (mg/dL)  
  Initial Day 15 Day 30 Negative  — 67.15 ± 2.63 74.24 ± 3.21** 75.39 ± 2.83** 
Control — 275.13 ± 2.21 311.18 ± 3.54 344.48 ± 4.21 
GLI 1 283.48 ± 2.27 167.35 ± 3.35** 99.28 ± 2.76** 
AMBE-L 40 292.37 ± 3.22 254.28 ± 3.84* 215.36 ± 3.83* 
AMBE-M 80 286.92 ± 2.48 229.49 ± 4.23** 158.45 ± 3.46** 
AMBE-H 160 276.74 ± 2.59 206.43 ± 3.27** 109.43 ± 3.52** 
Key: *p < 0.05，**p < 0.01 vs. control group. GLI: glibenclamide; AMBE-L: low dose of AMBE; AMBE-M: middle 
dose of AMBE; AMBE-H: high dose of AMBE 
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Table 2: Effect of AMBE on plasma insulin level in rats (mean ± SD, n = 10) 
 
Group Dose(mg/kg)  Plasma insulin (uU/ml)  
  Initial Day15 Day 30 Negative  — 18.35 ± 0.71 17.14 ± 0.86** 16.13 ± 0.52** 
Control — 6.22 ± 0.65 4.91 ± 0.74 3.84 ± 0.68 
GLI 1 5.87 ± 0.57 10.57 ± 0.79** 11.86 ± 0.75** 
AMBE-L 40 6.41 ± 0.53 6.82 ± 0.88* 7.62 ± 0.81* 
AMBE-M 80 5.84 ± 0.59 10.43 ± 0.91** 12.53 ± 0.88** 
AMBE-H 160 6.23 ± 0.48 11.78 ± 0.83** 13.96 ± 0.74** 
Key: *P < 0.05，**p < 0.01 vs. control group. GLI: glibenclamide; AMBE-L: low dose of AMBE; AMBE-M: middle 
dose of AMBE; AMBE-H: high dose of AMBE 
 
Effect of AMBE on biochemical parameters 
 
In order to examine the effect of AMBE on the 
regulation of biochemical parameters, creatinine 
and urea concentrations and total protein were 
studied to assess the renal function. STZ 
induced significant (p < 0.05) elevations in serum 
creatinine and urea levels and decrease in total 
protein when compared to normal group. 
However, treatment with different doses of AMBE 
significantly (p < 0.05) reduced serum creatinine 
and serum urea level and increased total protein 
when compared to those of diabetic control 
groups (Table 3). 
 
Effect of AMBE on oral glucose tolerance test 
(OGTT) 
 
The results indicated that the AMBE (160 mg/kg) 
and glibenclamide (1 mg/kg) reduced the blood 
glucose level (hyperglycemia due to glucose load 
2 g/kg p.o.) significantly (p < 0.05) after 120 min 
of oral administration, when compared to diabetic 
control (Table 4). 
 
Antioxidant status of rat liver and kidney 
tissue 
 
Oxidative stress assessment was performed by 
recording the activities of anti-oxidative enzymes 
i.e. catalase (CAT), Glutathioneperoxidase 
(GPx), superoxide dismutase (SOD), reduced 
glutathione (GSH) and lipid peroxidation. The 
diabetic rats showed significant (p < 0.05) 
increase in TBARS along with significantly 
decreased level of antioxidant enzymes i.e. CAT, 
GPx, GSH and SOD in hepatic and renal tissues. 
Treatment with AMBE significantly (p < 0.05) 
increased CAT, GPx, GSH and SOD in hepatic 
and renal tissues in diabetic rats. The increased 
level of TBARS was found to be reverted back to 
near normal status after treatment of AMBE (p < 
0.05) (Tables 5 and 6). The AMBE was found to 
possess antioxidant effect in a dose dependent 
manner. 
 
Table 3: Effect of AMBE on biochemical parameters in rats (mean ± SD, n = 10) 
 







 (mg/kg) (mg/dL)  (Hb%)  (mg/dL) (mg/dL) (g/dL) Negative  — 13.14±2.18* 6.62 ±0.79* 0.85 ±0.11* 33.87±1.76* 7.93 ±1.18* 
Control — 8.12±1.22 15.42 ±1.18 2.31 ±0.28 85.68±2.11 4.31 ±1.37 
GLI 1 10.34±2.48 12.51 ±0.82 0.89 ±0.29* 35.86±1.38* 7.41 ±1.42* 
AMBE-L 40 9.46±1.23* 12.37 ±0.88* 1.57 ±0.24* 75.74±2.33* 6.43 ±1.21* 
AMBE-M 80 10.69±1.76* 9.79 ±0.78* 1.19 ±0.22* 60.78±1.67* 6.87 ±1.25* 
AMBE-H 160 12.64±1.47* 8.05 ±0.81* 0.86 ±0.29* 45.14±1.79* 7.48 ±1.39* 
Key: *P < 0.05，**p < 0.01 vs. control group. GLI: glibenclamide; AMBE-L: low dose of AMBE; AMBE-M: middle 
dose of AMBE; AMBE-H: high dose of AMBE 
 
Table 4: Effect of AMBE on plasma insulin level in rats (mean ± SD, n = 10) 
 
Group Dose Fasting blood glucose level (mg/dL) at (h) 
 (mg/kg) 0h 0.5h 1h 1.5h 2h Negative — 91.7 ± 0.4 121.5 ± 1.4 127.4 ± 1.2 141.2 ± 1.3 145.2 ± 1.4 
Control — 253.3 ± 1.2 259.1 ± 0.7 276.3 ± 1.1 294.3 ± 1.1 311.6 ± 1.3 
GLI 1 249.2 ± 1.6 258.2 ± 1.1* 266.4 ± 1.2* 281.3 ± 1.5* 259.4 ± 1.4* 
AMBE-H 160 252.5 ± 1.4 253.2 ± 1.2* 267.2 ± 1.2* 288.4 ± 1.2* 269.2 ± 1.5* 
Key:*p < 0.05，**p < 0.01 vs. control group. GLI: glibenclamide; AMBE-H: high dose of AMBE 
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Table 5: Effect of AMBE on anti-oxidative enzymes of liver in rats (mean ± SD, n = 10) 
 
    Liver   Group Dose SOD CAT  GPx  GSH  TBARS 





protein) min/mg protein) 100 g tissue) 100 g tissue) 
Negative — 8.38 ±1.14* 84.86 ±2.14* 11.33 ±0.79* 55.23 ±1.79* 0.89 ±0.18* 
Control — 3.62 ±0.22 30.98 ±1.86 5.79 ±0.68 24.43 ±2.15 2.13 ±0.16 
GLI 1 6.19 ±0.33* 75.87 ±2.46* 10.15 ±1.28* 45.85 ±1.61* 0.89 ±0.23* 
AMBE-L 40 5.76 ±0.22 58.59 ±3.22* 7.79 ±1.12 40.14 ±2.23* 1.49 ±0.38 
AMBE-M 80 6.58 ±0.15* 67.94 ±2.85* 9.16 ±1.14* 46.25 ±2.65* 1.25 ±0.39* 
AMBE-H 160 7.83 ±0.18* 83.25 ±3.14 11.24 ±1.14* 49.21 ±2.59* 0.86 ±0.25* 
Key:*P < 0.05，**p < 0.01 vs. control group. GLI: glibenclamide; AMBE-L: low dose of AMBE; AMBE-M: middle 
dose of AMBE; AMBE-H: high dose of AMBE.TBARS: thiobarbituric Acid Reactive Substances 
 
Table 6: Effect of AMBE on anti-oxidative enzymes of kidney in rats (mean ± SD, n=10) 
 
    Kidney   Group Dose SOD CAT  GPx  GSH  TBARS 





protein) min/mg protein) 100 g tissue) 100 g tissue) 
Negative — 16.24±0.41* 73.27±2.53* 14.31±1.23* 36.97±1.38* 1.47±0.22* 
Control — 8.23±0.21 48.48±2.74 6.67±0.84 24.17±1.62 2.59±0.17 
GLI 1 13.06±0.32* 70.46±2.49* 11.47±0.85* 34.24±1.73* 1.85±0.26* 
AMBE-L 40 10.18±0.48 62.25±3.27* 10.23±1.38 30.17±1.45* 1.88±0.52 
AMBE-M 80 11.94±0.57* 68.86±3.39* 11.48±1.21* 32.73±1.36* 1.69±0.45* 
AMBE-H 160 14.13±0.49* 72.27±3.21* 11.96±1.16 34.56±1.14* 1.52±0.48* 
Key:*P < 0.05，**p < 0.01 vs. control group. GLI: glibenclamide; AMBE-L: low dose of AMBE; AMBE-M: middle 




The continuous treatment of AMBE for a period 
of 30 days produced a significant (p < 0.05) 
decrease in blood glucose levels in diabetic rats 
which is comparable to that of standard and 
diabetic control group. An increase in blood 
glucose seen in the oral glucose tolerance test 
(OGTT) was significantly greater in the diabetic 
rats than in the non-diabetic rats. The level of 
plasma insulin increased in non-diabetic rats, but 
unchanged in diabetic rats. Oral administration of 
AMBE 80 mg/kg significantly improved the 
impaired glucose tolerance in the diabetic rats 
with change in plasma insulin level. Considering 
the above result, the hypoglycemic effect of the 
plant may involve an insulin-like action i.e., acting 
at peripheral level to increase cellular glucose 
uptake or increase glycogenesis.  
 
A number of plants have been shown to exert 
hypoglycemic activity through stimulation of 
insulin release [15] like glibenclamide that has 
been reported to enhance the activity of beta 
cells of pancreas resulting in increased secretion 
of large amount of insulin which in turn brings 
down blood glucose level. It is assumed that the 
extract of Astragalus membranaceus may be 
responsible for stimulation of insulin and the 
observed restoration of metabolic activity. 
 
The diabetic hyperglycemia induces elevation of 
the serum level of urea and creatinine which has 
been considered as significant markers of renal 
dysfunction [16]. An increase in serum level of 
urea and creatinine levels in STZ-diabetic rats 
may indicate diminished ability of the kidney to 
filter these waste products from the blood and 
excrete them in the urine. On the other hand, the 
results indicate that treatment of diabetic group 
with Astragalus membranaceus (Fisch.) Bunge. 
extract significantly reduced serum urea and 
creatinine level. Based on these findings, the 
extract of this plant may enhance the ability of 
the kidney to remove these waste products from 
the blood, as indicated by a protective effect on 
the kidney of diabetic rats. 
 
Diabetes is strongly co-related with oxidative 
stress induction. Lipid peroxidation is one of the 
characteristic features of diabetes mellitus. 
Measurement of plasma thiobarbituric acid 
reactive substances (TBARS) was used as an 
index of lipid peroxidation and it helps to assess 
the extent of tissue damage [17]. Several studies 
have reported an increase in TBARS and 
hydroperoxides in plasma, liver and kidney in 
experimental diabetes mellitus [18]. The result of 
the present study showed that Astragalus 
membranaceus extract significantly (p < 0.05) 
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decreased TBARS level and reduced the risk of 
tissue damage. 
 
Oxidative stress in diabetes is coupled to a 
decrease in antioxidant status, which can 
increase the deleterious effects of free radicals. 
SOD and CAT are the two major scavenging 
enzymes that remove free radicals. Reduced 
activities of these antioxidant enzyme in liver, 
kidney and pancreas tissues have been 
observed in diabetic rats and this activity may 
result in a number of deleterious effects due to 
accumulation of superoxide anion (O) and 
hydrogen peroxide (H2O2), which in turn generate 
hydroxyl radicals (OH), resulting in initiation and 
propagation of LPO. SOD protects from oxygen 
free radicals by catalyzing the removal of 
superoxide radical, which damage the membrane 
and biological structures.  
 
Catalase has been shown to be responsible for 
the detoxification of H2O2, and protected the 
tissues from highly reactive hydroxyl radicals 
[19]. The decrease in CAT activity could have 
resulted from in activation by glycation of enzyme 
[20]. In the present study, extract treated groups 
showed a significant increase in the hepatic and 
renal SOD and CAT activities of the diabetic rats. 
This means that the extracts can reduce the 
potential glycation of enzymes or they may 
reduce reactive oxygen free radicals and improve 
the activities of antioxidant enzymes. This result 
clearly shows that Astragalus membranaceus 
(Fisch.) Bunge. contains a free radical 
scavenging activity, which could exert a 
beneficial action against pathological alteration 
caused by the presence of superoxide radicals 




This study shows that Astragalus membranaceus 
(Fisch.) Bunge. extract possesses potent 
antioxidant activity which may be responsible for 
its hypoglycemic property. Further 
pharmacological and biochemical investigations 
are underway to determine the active 
constituents responsible for its antidiabetic 
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